(STVN) Stevanato SpA - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 4.917m USD | Total Return: -21.1% in 12m
Avg Turnover: 8.07M
EPS Trend: -13.2%
Qual. Beats: 0
Rev. Trend: 97.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Stevanato Group S.p.A. (STVN) is an Italian-based provider of drug containment, delivery, and diagnostic solutions for the global pharmaceutical and life sciences industries. The company operates through two primary segments: Biopharmaceutical and Diagnostic Solutions, which focuses on glass containers and delivery systems like auto-injectors, and Engineering, which designs specialized equipment for pharmaceutical assembly and inspection.
The business model relies on integrated high-value solutions, where specialized glass primary packaging is increasingly paired with proprietary drug delivery devices to support complex biologics. Within the Health Care Equipment sector, companies like Stevanato benefit from high switching costs due to rigorous regulatory requirements for drug-contact materials and manufacturing processes.
Investors can evaluate the long-term growth drivers for this medical technology firm by reviewing the detailed financial metrics available on ValueRay.
Founded in 1949, Stevanato serves a broad client base including biotechnology firms and contract manufacturing organizations (CMOs) across five continents. Its portfolio extends from initial drug development support and analytical services to large-scale automated packaging and glass-converting machinery.
- Transition to high-value biologics solutions improves gross margins and average selling prices
- Rising demand for GLP-1 weight loss drugs accelerates pre-fillable syringe volume growth
- Capital expenditure for global capacity expansion impacts short-term free cash flow generation
- Biopharma inventory destocking cycles influence quarterly revenue timing and organic growth rates
- Engineering segment backlog levels signal future adoption of automated drug delivery systems
| Net Income: 140.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 7.21 > 1.0 |
| NWC/Revenue: 29.51% < 20% (prev 33.99%; Δ -4.48% < -1%) |
| CFO/TA 0.10 > 3% & CFO 260.1m > Net Income 140.9m |
| Net Debt (352.4m) to EBITDA (290.5m): 1.21 < 3 |
| Current Ratio: 1.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (273.0m) vs 12m ago 0.04% < -2% |
| Gross Margin: 29.01% > 18% (prev 0.28%; Δ 2.87k% > 0.5%) |
| Asset Turnover: 48.90% > 50% (prev 48.39%; Δ 0.51% > 0%) |
| Interest Coverage Ratio: 21.53 > 6 (EBITDA TTM 290.5m / Interest Expense TTM 9.20m) |
| A: 0.14 (Total Current Assets 914.4m - Total Current Liabilities 560.3m) / Total Assets 2.58b |
| B: 0.39 (Retained Earnings 1.02b / Total Assets 2.58b) |
| C: 0.08 (EBIT TTM 198.1m / Avg Total Assets 2.45b) |
| D: 0.95 (Book Value of Equity 998.3m / Total Liabilities 1.05b) |
| Altman-Z'' = 3.72 = AA |
| DSRI: 0.97 (Receivables 506.7m/487.6m, Revenue 1.20b/1.12b) |
| GMI: 0.95 (GM 29.01% / 27.57%) |
| AQI: 0.94 (AQ_t 0.08 / AQ_t-1 0.08) |
| SGI: 1.07 (Revenue 1.20b / 1.12b) |
| TATA: -0.05 (NI 140.9m - CFO 260.1m) / TA 2.58b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 17.97 with a total of 118,645 shares traded.
Over the past week, the price has changed by +1.01%,
over one month by +11.06%,
over three months by +17.37% and
over the past year by -21.10%.
Stevanato SpA has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy STVN.
- StrongBuy: 6
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24.8 | 38.2% |
Market Cap EUR = 4.22b (4.92b USD * 0.859 USD.EUR)
P/E Trailing = 30.5254
P/E Forward = 19.4553
P/S = 4.0862
P/B = 2.7631
P/EG = 3.5691
Revenue TTM = 1.20b EUR
EBIT TTM = 198.1m EUR
EBITDA TTM = 290.5m EUR
Long Term Debt = 312.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 124.8m EUR (from shortTermDebt, last quarter)
Debt = 465.1m EUR (from shortLongTermDebtTotal, last quarter) + Leases 16.6m
Net Debt = 352.4m EUR (calculated: Debt 465.1m - CCE 112.7m)
Enterprise Value = 4.58b EUR (4.22b + Debt 465.1m - CCE 112.7m)
Interest Coverage Ratio = 21.53 (Ebit TTM 198.1m / Interest Expense TTM 9.20m)
EV/FCF = -644.0x (Enterprise Value 4.58b / FCF TTM -7.11m)
FCF Yield = -0.16% (FCF TTM -7.11m / Enterprise Value 4.58b)
FCF Margin = -0.59% (FCF TTM -7.11m / Revenue TTM 1.20b)
Net Margin = 11.75% (Net Income TTM 140.9m / Revenue TTM 1.20b)
Gross Margin = 29.01% ((Revenue TTM 1.20b - Cost of Revenue TTM 851.9m) / Revenue TTM)
Gross Margin QoQ = 27.48% (prev 30.85%)
Tobins Q-Ratio = 1.77 (Enterprise Value 4.58b / Total Assets 2.58b)
Interest Expense / Debt = 1.98% (Interest Expense 9.20m / Debt 465.1m)
Taxrate = 28.57% (11.2m / 39.2m)
NOPAT = 141.5m (EBIT 198.1m * (1 - 28.57%))
Current Ratio = 1.63 (Total Current Assets 914.4m / Total Current Liabilities 560.3m)
Debt / Equity = 0.30 (Debt 465.1m / totalStockholderEquity, last quarter 1.53b)
Debt / EBITDA = 1.21 (Net Debt 352.4m / EBITDA 290.5m)
Debt / FCF = -49.60 (negative FCF - burning cash) (Net Debt 352.4m / FCF TTM -7.11m)
Total Stockholder Equity = 1.46b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.74% (Net Income 140.9m / Total Assets 2.58b)
RoE = 9.63% (Net Income TTM 140.9m / Total Stockholder Equity 1.46b)
RoCE = 11.16% (EBIT 198.1m / Capital Employed (Equity 1.46b + L.T.Debt 312.6m))
RoIC = 6.87% (NOPAT 141.5m / Invested Capital 2.06b)
WACC = 6.76% (E(4.22b)/V(4.69b) * Re(7.35%) + D(465.1m)/V(4.69b) * Rd(1.98%) * (1-Tc(0.29)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 1.25%
[DCF] Fair Price = unknown (Cash Flow -7.11m)
EPS Correlation: -13.23 | EPS CAGR: -1.26% | SUE: 0.79 | # QB: 0
Revenue Correlation: 97.92 | Revenue CAGR: 5.17% | SUE: 0.26 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.15 | Chg30d=-2.03% | Revisions=-9% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.19 | Chg30d=+0.38% | Revisions=+50% | Analysts=9
EPS current Year (2026-12-31): EPS=0.71 | Chg30d=+1.31% | Revisions=+71% | GrowthEPS=+13.8% | GrowthRev=+7.6%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=-0.55% | Revisions=+23% | GrowthEPS=+19.3% | GrowthRev=+9.8%
[Analyst] Revisions Ratio: +71%